Jul 8 |
REVB Releases Positive Test Results—Potential Catalyst
|
Jun 24 |
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
|
Jun 24 |
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
|
Jun 13 |
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
|
May 13 |
REVB: In Great Position For Testing
|
May 10 |
Revelation Biosciences GAAP EPS of -$2.46
|
May 10 |
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
|